	US 12,447,201 B2
	Immunogenic compounds for cancer therapy
Laurent Chene, Neuville Aux Bois (FR); Alban Mathieu, Saint Foy les Lyon (FR); and Matthieu Pichaud, Cambridge, MA (US)
Assigned to ENTEROME S.A., Paris (FR)
Filed by ENTEROME S.A., Paris (FR)
Filed on Jun. 24, 2024, as Appl. No. 18/751,502.
Application 18/751,502 is a continuation of application No. 17/929,063, filed on Sep. 1, 2022, granted, now 12,059,460.
Application 17/929,063 is a continuation of application No. 16/338,955, granted, now 11,478,538, issued on Oct. 25, 2022, previously published as PCT/EP2017/075676, filed on Oct. 9, 2017.
Claims priority of application No. 16192954 (EP), filed on Oct. 7, 2016.
Prior Publication US 2024/0342261 A1, Oct. 17, 2024
Int. Cl. A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61P 35/00 (2006.01)

CPC A61K 39/00114 (2018.08) [A61K 39/0011 (2013.01); A61K 39/39 (2013.01); A61P 35/00 (2018.01); A61K 2039/5158 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/572 (2013.01); A61K 2039/6031 (2013.01)]

20 Claims

1. An immunogenic compound comprising an antigenic peptide comprising an amino acid sequence as set forth in SEQ ID NO: 142.